LLY compared with CBIO: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

CBIOCrescent Biopharma, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

CBIOCrescent Biopharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

LLYELI Lilly & Co

1,407.25▼−0.27%· post 1,406.57· delayed

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

CBIOCrescent Biopharma, Inc.

13.55▲+4.94%· post 13.10· delayed

After hoursNov 3 '26delayed

Mkt cap$479.5MRevenue$1MQ1 FY26Revenue—

Compare

After hoursNov 3 '26delayed

LLYELI Lilly & Co

CBIOCrescent Biopharma, Inc.

1,407.25▼−0.27%post 1,406.57delayed

Price

13.55▲+4.94%post 13.10delayed

$1.3T

Mkt cap

$479.5M

Q3 FY26$24.4B

Revenue

$1MQ1 FY26

FY25$65.2B

Revenue

—

LLY1,407.25▼−0.27%vsCBIO13.55▲+4.94%After hoursNov 3 '26delayed

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

CBIO: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

25 more · LLY chain ›

Shared 0

No shared counterparties.

Only CBIO 5

CRLCharles River Laboratoriessupplier

—Paragon Therapeuticsunlistedsupplier

—WuXi Biologics (Hong Kong)unlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

WuXi Biologics Ireland

unlistedsupplier

1 more · CBIO chain ›

Price

rebased to 0%

LLY, solidCBIO, dashed